Treeline Biosciences opens Phase 1 study of TLN-499 in relapsed tumors
The first-in-human trial will test safety and dosing of TLN-499 across four hard-to-treat cancers, entering a small-molecule field with no disclosed target for the drug itself.
Executive Summary
- Treeline Biosciences is starting a Phase 1 dose-escalation study of TLN-499, its first clinical trial of the compound, in patients whose tumors have relapsed or resisted prior treatment.
- The study spans four distinct, difficult-to-treat cancers rather than a single indication, and pairs standard safety and pharmacokinetic measures with an early tumor-response endpoint in the same cohort.
- TLN-499 enters a small-molecule field that is heavily populated in lung cancer overall, but its own target and mechanism are not yet established on the record, so it cannot be positioned against any specific competing drug class.
- As an early, non-registrational study, the trial's near-term value is establishing a tolerable dose and any hint of activity, not resolving whether TLN-499 will ultimately compete with an approved standard of care.
The trial
The study, registered as NCT07713732 and titled "Phase 1 Safety and Pharmacokinetics Study in Patients With Relapsed/Refractory Tumors," is not yet recruiting and plans to enroll 120 patients. It will run at sites in Australia and carries a primary completion date of August 29, 2030, giving it a trial duration of roughly four years. The design is open-label with a single arm and no masking, standard for a first-in-human dose-escalation study. NCT07713732Phase 1 Safety and Pharmacokinetics Study in Patients With Relapsed/Refractory Solid TumorsNCT07713732
The design
The trial lists three co-primary measures: incidence of treatment-emergent adverse events and serious adverse events, incidence of dose-limiting toxicities during the first 35 days of treatment, and overall response rate assessed by RECIST v1.1 or, for mesothelioma, modified RECIST. Secondary endpoints track pharmacokinetic parameters (AUC, Cmax, Cmin, Tmax), along with duration of response, progression-free survival, and overall survival. Enrolled patients must be at least 18 years old with measurable disease and an ECOG performance status of 0 to 1, and must have received at least one prior line of therapy. NCT07713732Phase 1 Safety and Pharmacokinetics Study in Patients With Relapsed/Refractory Solid TumorsNCT07713732
The landscape
TLN-499's target and mechanism of action are not established in available records, so the trial cannot be benchmarked against a specific competing drug class on that basis. Small-molecule development in this indication family is active broadly: 276 trials have used small-molecule agents in small cell lung cancer alone. The closest comparators identified share modality (small molecule or antibody-based) but different targets, including AstraZeneca's osimertinib, Merck's calderasib, and Boehringer Ingelheim's zongertinib, each running in later-phase non-small cell lung cancer trials rather than the four indications TLN-499 targets. No trial sharing TLN-499's specific target could be identified, which reflects the target itself not being characterized rather than a claim about the mechanism's novelty.
Sponsor context
Treeline Biosciences has three other trials in its portfolio, all still recruiting, alongside this newly registered study, and carries no prior terminated trials on record. This is the sponsor's first registered trial of TLN-499, and no completed, terminated, or withdrawn trials of the compound exist yet in any indication or phase.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.